https://www.selleckchem.com/products/AZD0530.html
001). We found that SOX9 is significantly overexpressed in high-grade PC tumors (P less then 0.05) and in chemotherapy-treated patients compared to chemo-naïve patients (P less then 0.05). These results were further validated using publicly available datasets. Moreover, afatinib alone or in combination with gemcitabine decreased stemness and tumorspheres by reducing phosphorylation of EGFR family proteins, ERK, FAK, and CSC markers. Mechanistically, afatinib treatment decreased CSC markers by downregulating SOX9 via FOXA2. Indeed, E
Like
Comment
Share
